Archive for the ‘bharat aggarwal’ Category
A cancer researcher has earned seven more retractions following an investigation into his work by his former employer, MD Anderson Cancer Center in Texas, bringing his total to 18 retractions.
All of the new retraction notices, issued by The Journal of Biological Chemistry (JBC), stem from image-related issues. The now-retired Aggarwal has seven papers that have each been cited at least 1,000 times, and in 2015, he was on Thomson Reuters Web of Science’s list of The World’s Most Influential Scientific Minds. With these new notices, he also has made it to our leaderboard of individual researchers who’ve racked up the most retractions.
An MD Anderson spokesperson sent us this statement: Read the rest of this entry »
More scientists are trying to settle accusations of misconduct in court, a trend very familiar to Washington, DC-based lawyer Paul Thaler. Regular readers may recall the name of one of Thaler’s clients — Rakesh Kumar, a scientist at George Washington University who filed an $8 million lawsuit for how the school handled an investigation into his work. He’s also representing Bharat Aggarwal, the subject of an investigation at MD Anderson who has threatened to sue us (and logged his ninth retraction this week). For 25 years, Thaler has been representing scientists embroiled in misconduct proceedings. He spoke to us about his family’s highly pedigreed background in science, and why everyone deserves an advocate.
Some of your clients have committed misconduct, but you still work to protect their reputations and even help them continue to do research. Why?
Bharat Aggarwal, a highly cited cancer researcher who retired last year from MD Anderson, has logged two retractions following an investigation into his work, bringing his total to nine.
Aggarwal has threatened to sue us in the past, and told us that MD Anderson has been investigating his work. Earlier this year, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” Now, he’s earned two more retractions in Molecular Pharmacology, both for “inappropriate” or “unacceptable” image manipulation.
Both of the notices are paywalled (tsk, tsk). Here’s one for “Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells:” Read the rest of this entry »
A cancer researcher who recently retired from MD Anderson Cancer Center — and also recently lost seven papers from one journal following a multi-year investigation — is one of the world’s top scientists, according to a new ranking.
In Thomson Reuters Web of Science’s 2015 list of The World’s Most Influential Scientific Minds, Bharat Aggarwal’s name tops the section for Pharmacology and Toxicology (see p. 89). In all fairness, the list is presented in alphabetical order, and seven of Aggarwal’s papers have each been cited at least 1,000 times. But in addition to his recent seven retractions, he has has six corrections, two unexplained withdrawals, and two Expressions of Concern.
We contacted Thomson Reuters Web of Science to inquire, and a spokesperson told us: Read the rest of this entry »
An MD Anderson Cancer Center researcher who has been under investigation by the institution for at least several years has had seven papers retracted from a single journal.
Bharat Aggarwal told us in 2012 that MD Anderson was investigating his work, but in 2013 threatened to sue us for reporting on the case. Aggarwal is no longer listed in the MD Anderson directory, and an email to him there bounced.
This week, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” The papers have been cited a total of more than 500 times, according to Thomson Scientific’s Web of Knowledge; one has been designated as “highly cited.” Here are the seven retractions: Read the rest of this entry »
Bharat Aggarwal is the last author on all three papers. He is now up to six corrections, two unexplained withdrawals, and two Expressions of Concern. He’s also threatened to sue us in the past, and has told us that his institution has been looking into his work.
Only one note specifies that the correction does not affect the paper’s conclusions.
First up: “Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling,” published in the International Journal of Cancer and cited 168 times, according to Thomson Scientific’s Web of Knowledge. The issues span two figures, according to the erratum note:
Here’s the notice for “Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors:” Read the rest of this entry »
Two Expressions of Concern in Blood for MD Anderson’s Aggarwal, who has threatened to sue Retraction Watch
Bharat Aggarwal, the MD Anderson researcher who has threatened to sue us while under investigation by his institution for alleged misconduct, now has two Expressions of Concern in addition to two corrections and two unexplained withdrawals.
Both of the papers were published in Blood. The Expression of Concern for “Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway,” reads: Read the rest of this entry »
When we learned earlier this week that Bharat Aggarwal, the MD Anderson researcher under investigation there for possible misconduct, had directed his attorneys to send us a pull-all-your-posts-about-our-client-or-we’ll-sue-you letter, we wondered if he’d included the Houston institution in that decision.
Turns out he’d been acting on his own. Read the rest of this entry »
Today, we received a letter from the Houston firm of Paranjpe & Mahadass LLP telling us to pull every post related to their client off our site within 20 days, or they’d “file a lawsuit against” us on his behalf.